LTR PHARMA FPO (ASX: LTP) — Company Overview, News & Financial Data
LTR PHARMA FPO is a clinical-stage biopharmaceutical company focused on improving men's health through the development and commercialisation of fast-acting delivery platforms.
LTR PHARMA FPO
LTR PHARMA FPO is a clinical-stage biopharmaceutical company focused on improving men's health through the development and commercialisation of fast-acting delivery platforms. The company's lead product candidate, SPONTAN, is a novel intranasal spray formulation of a phosphodiesterase-5 inhibitor designed for the rapid on-demand treatment of erectile dysfunction. Beyond its core intranasal delivery technology, the business expands its men's health portfolio through distribution and commercialisation agreements for approved treatments, including oral testosterone replacement therapies. Based in Australia, the company conducts clinical development, regulatory filings, and commercial partnerships to disrupt traditional oral tablet markets.
Snapshot
Operations
Products and/or services of LTR PHARMA FPO
- Erectile Dysfunction Therapeutics: Intranasal vardenafil delivery platform engineered for rapid absorption and onset of action within ten minutes, providing on-demand treatment for erectile dysfunction with reduced systemic exposure compared to oral PDE5 inhibitor tablets.
- Testosterone Replacement Therapies: Commercialisation and distribution of FDA-approved oral testosterone undecanoate capsules in Australia, offering targeted treatment options for men suffering from testosterone deficiency, low energy, and related metabolic conditions.
- Special Access Scheme Access: Early patient access program supplying nasal spray formulations directly to qualified healthcare practitioners and eligible patients across Australia under Therapeutic Goods Administration regulatory frameworks prior to full market authorization.
- Clinical Study Programs: Execution of Phase II pharmacokinetic trials and bioequivalence datasets to support streamlined regulatory submissions, including United States Food and Drug Administration Section 505(b)(2) New Drug Application approval pathways.
LTR PHARMA FPO executive team
- Lee RodneExecutive Chairman
- Jacques SchipperChief Financial Officer
- Peter McLennanChief Operating Officer
- Geoffrey A. StrangeChief Medical Officer
- Danny ZanardoChief Commercial Officer
- Euh HwangJoint Company Secretary
- Elizabeth SpoonerJoint Company Secretary
Latest news about LTR PHARMA FPO
LTR Pharma completes key study achieving sixfold faster absorption
AustraliaLTR Pharma books $19.7M cash reserves, zero debt in FY26
AustraliaLTR Pharma signs deal to deliver 150,000 ROXUS units
AustraliaLTR Pharma secures US telehealth deal for ROXUS
AustraliaLTR Pharma completes recruitment for SPONTAN Phase 2 study
AustraliaLTR Pharma begins Phase 2 trial of SPONTAN for ED
Australia
Recent announcements
What LTR PHARMA FPO (LTP) has told the market, newest first.
- Investor Webinar Presentation
- First ROXUS Prescriptions Fulfilled in the United StatesPrice sensitive
- Clinical and Commercial Update - Investor Webinar
- SPONTAN Phase II Final ResultsPrice sensitive
Key financials
Reported results for LTR PHARMA FPO, in AUD.
- Market cap
- 78.4M
- Revenue (TTM)
- 723.9K
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.1
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 183.9K | -14.5M | -14.2M | |
| 2.1M | -5.2M | -5.6M | |
| 49.3K | -6.4M | -7M | |
| 90 | -1.4M | -1.5M |